Cargando…

Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention

BACKGROUND: Nicorandil is a nicotinamide ester commonly prescribed for treatment of patients with coronary heart disease (CHD). In the present study, we aimed to explore the cardioprotective effects of nicorandil on CHD patients undergoing elective percutaneous coronary intervention (PCI). MATERIAL/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pang, Zhihua, Zhao, Wei, Yao, Zhuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2017
Materias:	Product Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484606/ https://www.ncbi.nlm.nih.gov/pubmed/28617765 http://dx.doi.org/10.12659/MSM.902324

Ejemplares similares

Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention
por: Yang, Jing, et al.
Publicado: (2015)

Efficacy and safety of nicorandil on perioperative myocardial injury in patients undergoing elective percutaneous coronary intervention: results of the PENMIPCI trial
por: Ye, Ziliang, et al.
Publicado: (2018)

Prognostic value of mean platelet volume in patients undergoing elective percutaneous coronary intervention
por: Seyyed-Mohammadzad, Mir Hossein, et al.
Publicado: (2015)

Impact of intracoronary nicorandil before stent deployment in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Xu, Xingli, et al.
Publicado: (2020)

Effects of nicorandil on systemic inflammation and oxidative stress induced by percutaneous coronary intervention in patients with coronary heart disease
por: Zong, Yulong, et al.
Publicado: (2021)

Sustained nicorandil administration reduces the infarct size in ST-segment elevation myocardial infarction patients with primary percutaneous coronary intervention
por: Wang, Shanjie, et al.
Publicado: (2019)

Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention
por: Zhao, Xiao-Tao, et al.
Publicado: (2019)

Cardio protective effect of nicorandil in reperfusion injury among patients undergoing primary percutaneous coronary intervention
por: Ilyas, Maria, et al.
Publicado: (2023)

Intracoronary application of nicorandil regulates the inflammatory response induced by percutaneous coronary intervention
por: Hu, Keqing, et al.
Publicado: (2020)

Efficacy and Safety of Nicorandil in Preventing Contrast-Induced Nephropathy after Elective Percutaneous Coronary Intervention: A Pooled Analysis of 1229 Patients
por: Yi, Bin, et al.
Publicado: (2020)

Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: A randomized controlled trial
por: Zhang, Weifeng, et al.
Publicado: (2021)

Nicorandil in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
por: Wu, Muli, et al.
Publicado: (2013)

Renoprotective effect of nicorandil in patients undergoing percutaneous coronary intervention: a meta-analysis of 4 randomized controlled trials
por: Wang, Xiaobing, et al.
Publicado: (2018)

Effects of mitochondrial ATP-sensitive potassium channel activation (nicorandil) in patients with angina pectoris undergoing elective percutaneous coronary interventions: A meta-analysis of randomized controlled trials
por: Zhu, Houyong, et al.
Publicado: (2019)

Effects of nicorandil infusion on ECG parameters in patients with unstable angina pectoris and percutaneous coronary intervention
por: Wang, Weiding, et al.
Publicado: (2019)

Direct inhibitory effects of Ganciclovir on ICAM-1 expression and proliferation in human coronary vascular cells (SI/MPL-ratio: >1)
por: Voisard, Rainer, et al.
Publicado: (2011)

Cardioprotective Effects of Atorvastatin plus Trimetazidine in Percutaneous Coronary Intervention
por: Lin, Xuefeng, et al.
Publicado: (2013)

Assessment of the Efficacy and Safety of Early Intracoronary Nicorandil Administration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Gupta, Himanshu, et al.
Publicado: (2022)

Left Ventricular Twist and Untwist in Patients Undergoing Elective Percutaneous Coronary Intervention
por: Elzieny, Ali A., et al.
Publicado: (2021)

Incident Heart Failure in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Gu, Jun, et al.
Publicado: (2021)

Intracoronary administration of nicorandil-induced cardiac arrest during primary percutaneous coronary intervention: A case report
por: Wei, Shu-Jian, et al.
Publicado: (2019)

Effects of Nicorandil Administration on Infarct Size in Patients With ST‐Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The CHANGE Trial
por: Qian, Geng, et al.
Publicado: (2022)

Patient Symptoms and Stress Testing After Elective Percutaneous Coronary Intervention in the Veterans Affairs Health Care System
por: Kini, Vinay, et al.
Publicado: (2022)

Prognostic implication of serum glycated albumin for patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention
por: Liu, Chi, et al.
Publicado: (2022)

Temporal trends in prevalence and outcomes of atrial fibrillation in patients undergoing percutaneous coronary intervention
por: Morita, Yusuke, et al.
Publicado: (2019)

The independent impact of dementia in patients undergoing percutaneous coronary intervention for acute myocardial infarction
por: Kodesh, Afek, et al.
Publicado: (2023)

Effect of nicorandil administration on myocardial microcirculation during primary percutaneous coronary intervention in patients with acute myocardial infarction
por: Feng, Chunguang, et al.
Publicado: (2018)

Prognostic Value of Cardiac Troponin T and Sex in Patients Undergoing Elective Percutaneous Coronary Intervention
por: Harada, Yukinori, et al.
Publicado: (2016)

Effects of Baseline Thrombocytopenia on In-hospital Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention
por: Shiraishi, Jun, et al.
Publicado: (2019)

Periprocedural myocardial and renal injury in patients undergoing elective percutaneous coronary interventions – is there an association?
por: Stipinovic, Mario, et al.
Publicado: (2019)

Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study
por: De Luca, Leonardo, et al.
Publicado: (2022)

Changes in Heart Rate Variability Parameters after Elective Percutaneous Coronary Intervention
por: Abrootan, Saeed, et al.
Publicado: (2015)

Long-term oral nitrate therapy is associated with adverse outcome in diabetic patients following elective percutaneous coronary intervention
por: Hang Yiu, Kai, et al.
Publicado: (2011)

Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention
por: Huang, Zhuoshan, et al.
Publicado: (2020)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Two-year prognostic value of mean platelet volume in patients with diabetes and stable coronary artery disease undergoing elective percutaneous coronary intervention
por: Jiang, Ping, et al.
Publicado: (2019)

Multimarker risk stratification approach and cardiovascular outcomes in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention
por: Mehta, Vimal, et al.
Publicado: (2016)

The Impact of Prediabetes on Two-Year Clinical Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention
por: Choi, Woong gil, et al.
Publicado: (2018)

Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials
por: Geng, Ning, et al.
Publicado: (2021)

Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention
por: Takahashi, Shuhei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rn0hpblsehcuhhjgn294t5t03i